Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial Journal Article

   

Authors:	Horwitz, S.; Zinzani, P. L.; Bagot, M.; Kim, Y. H.; Moskowitz, A. J.; Porcu, P.; Dwyer, K.; Sun, W.; Herr, F. M.; Scarisbrick, J.
Article Title:	Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial
Abstract:	Patients with mycosis fungoides (MF) and Sézary syndrome (SS) often require multiple lines of systemic therapy. In the phase 3 MAVORIC study (NCT01728805), mogamulizumab demonstrated superiority to vorinostat in median progression-free survival (PFS) and confirmed overall response rate (ORR) in patients with MF/SS. This post hoc analysis examined the effects of number and type of prior systemic therapies on mogamulizumab response. MAVORIC patients randomized to mogamulizumab (1.0 mg/kg intravenously weekly) or vorinostat (400 mg orally daily) were grouped by number of prior therapies and immunomodulatory activity of immediate prior systemic therapy while also considering time elapsed since treatment. ORR, PFS, and duration of response (DOR) did not vary with number of prior therapies. ORR and DOR remained consistent regardless of immediate prior therapy type. Additionally, immunomodulatory activity of the last prior therapy and time from prior treatment generally did not affect the ORR or PFS observed in response to mogamulizumab. © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Keywords:	adult; controlled study; treatment outcome; aged; major clinical study; lenalidomide; prednisone; cisplatin; doxorubicin; drug dose reduction; side effect; systemic therapy; treatment duration; gemcitabine; cytarabine; methotrexate; drug megadose; peginterferon alpha2b; low drug dose; progression free survival; multiple cycle treatment; etoposide; cyclophosphamide; steroid; vincristine; ifosfamide; docetaxel; prednisolone; cutaneous t-cell lymphoma; cutaneous t cell lymphoma; gamma interferon; vorinostat; open study; immunomodulation; hydroxychloroquine; methylprednisolone; isotretinoin; romidepsin; mycosis fungoides; pralatrexate; alemtuzumab; belinostat; cladribine; gamma1b interferon; triamcinolone; post hoc analysis; randomized controlled trial (topic); phase 3 clinical trial (topic); fludrocortisone; etretin; bexarotene; overall response rate; photopheresis; etretinate; brentuximab vedotin; quisinostat; nivolumab; human; male; female; article; bucladesine; mogamulizumab; treatment response time; sézary syndrome; prior systemic therapy; forodesine; ixazomib citrate
Journal Title:	Leukemia and Lymphoma
Volume:	62
Issue:	13
ISSN:	1042-8194
Publisher:	Taylor & Francis Group
Date Published:	2021-01-01
Start Page:	3109
End Page:	3118
Language:	English
DOI:	10.1080/10428194.2021.1953007
PUBMED:	34304674
PROVIDER:	scopus
PMCID:	PMC9447791
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111468905&doi=10.1080%2f10428194.2021.1953007&partnerID=40&md5=48dc62f2bd0e3192d8344b85b442655f
Notes:	Article -- Export Date: 3 January 2022 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/191760